2020年三季度发表的生信SCI，按照期刊接收的文章数量排序，TOP10的期刊是：OncolLett（2.31分）、FrontOncol（4.85分）、BiomedRes Int（2.28分）、CancerCell Int（4.18分）、Aging (Albany NY)（4.83分）、Cancers （6.126分）、Int J Immunopharmacol（3.94分）、Front Genet（3.26 分）、J CELL MOL MED（4.49分）、OncoTargets Ther（3.34分）。（小编惊喜的发现这个排名与2020年上半年生信SCI友好期刊排名竟大同小异，果然称得上生信友好期刊！）
|
2020生信友好期刊 |
接收量 |
最新IF |
|
OncolLett |
49 |
2.311 |
|
FrontOncol |
48 |
4.848 |
|
BiomedRes Int |
40 |
2.276 |
|
CancerCell Int |
35 |
4.175 |
|
Aging (Albany NY) |
34 |
4.83 |
|
Cancers |
32 |
6.126 |
|
Int J Immunopharmacol |
31 |
3.943 |
|
Front Genet |
27 |
3.258 |
|
J CELL MOL MED |
26 |
4.486 |
|
OncoTargets Ther |
26 |
3.337 |
|
Biosci Rep |
23 |
2.942 |
|
Cancer Med |
23 |
3.491 |
|
Medicine |
23 |
1.552 |
|
Sci Rep |
23 |
3.998 |
|
J Cancer |
22 |
3.565 |
|
BMC cancer |
19 |
3.150 |
|
Mol Med Rep |
17 |
2.100 |
|
Am J Transl Res |
15 |
3.375 |
|
Cancer Manag Res |
15 |
2.886 |
|
DNA Cell Biol |
15 |
3.191 |
|
Med Sci Monitor |
15 |
1.92 |
|
Genomics |
14 |
6.205 |
|
Theranostics |
14 |
8.579 |
|
Gene |
13 |
2.984 |
|
J Transl Med |
13 |
4.124 |
|
Oncol Rep |
13 |
3.417 |
|
Exp Ther Med |
12 |
1.785 |
|
Pathol Res Pract |
12 |
2.06 |
|
PeerJ |
12 |
2.379 |
|
PloS one |
11 |
2.740 |
|
Cancer Immunol Immun |
10 |
5.44 |
|
Front Cell Dev Biol |
10 |
5.201 |
|
J Cancer Res Clin Oncol |
10 |
3.656 |
|
J Cell Physiol |
10 |
5.546 |
|
J Comput Biol |
10 |
1.05 |
|
BMC Med Genomics |
9 |
2.570 |
|
Com Chem High T Sci |
9 |
1.195 |
|
Clin Cancer Res |
8 |
10.11 |
|
Eur Rev Med Pharmaco |
8 |
3.024 |
|
Front Pharmacol |
8 |
4.225 |
|
Int J Cancer |
8 |
5.145 |
|
Int J Mol Sci |
8 |
4.556 |
|
J Exp Clin Cancer Res |
8 |
7.07 |
|
Bioinformatics |
7 |
5.62 |
|
Int J Med Sci |
7 |
2.523 |
|
Life Sci |
7 |
3.647 |
|
Brief Bioinform |
6 |
8.990 |
|
Cell Death & Dis |
6 |
6.304 |
|
J Cell Biochem |
6 |
4.237 |
|
J Thorac Oncol |
6 |
2.206 |
|
J Int Med Res |
6 |
1.29 |
生信SCI友好期刊影响因子排序：
|
2020生信友好期刊 |
2020-IF因子 |
接收量 |
|
Clin Cancer Res |
10.107 |
8.00 |
|
Brief Bioinform |
8.990 |
6.00 |
|
Theranostics |
8.579 |
14.00 |
|
J Exp Clin Cancer Res |
7.068 |
8.00 |
|
Cell Death & Dis |
6.304 |
6.00 |
|
Genomics |
6.205 |
14.00 |
|
Cancers |
6.126 |
32.00 |
|
Bioinformatics |
5.615 |
7.00 |
|
J Cell Physiol |
5.546 |
10.00 |
|
Cancer Immunol Immun |
5.442 |
10.00 |
|
Front Cell Dev Biol |
5.201 |
10.00 |
|
Int J Cancer |
5.145 |
8.00 |
|
FrontOncol |
4.848 |
48.00 |
|
Aging (Albany NY) |
4.831 |
34.00 |
|
Int J Mol Sci |
4.556 |
8.00 |
|
J CELL MOL MED |
4.486 |
26.00 |
|
J Cell Biochem |
4.237 |
6.00 |
|
Front Pharmacol |
4.225 |
8.00 |
|
CancerCell Int |
4.175 |
35.00 |
|
J Transl Med |
4.124 |
13.00 |
|
Sci Rep |
3.998 |
23.00 |
|
Int J Immunopharmacol |
3.943 |
31.00 |
|
J Cancer Res Clin Oncol |
3.656 |
10.00 |
|
Life Sci |
3.647 |
7.00 |
|
J Cancer |
3.565 |
22.00 |
|
Cancer Med |
3.491 |
23.00 |
|
Oncol Rep |
3.417 |
13.00 |
|
Am J Transl Res |
3.375 |
15.00 |
|
OncoTargets Ther |
3.337 |
26.00 |
|
Front Genet |
3.258 |
27.00 |
|
DNA Cell Biol |
3.191 |
15.00 |
|
BMC cancer |
3.150 |
19.00 |
|
Eur Rev Med Pharmaco |
3.024 |
8.00 |
|
Gene |
2.984 |
13.00 |
|
Biosci Rep |
2.942 |
23.00 |
|
Cancer Manag Res |
2.886 |
15.00 |
|
PloS one |
2.740 |
11.00 |
|
BMC Med Genomics |
2.570 |
9.00 |
|
Int J Med Sci |
2.523 |
7.00 |
|
PeerJ |
2.379 |
12.00 |
|
OncolLett |
2.311 |
49.00 |
|
BiomedRes Int |
2.276 |
40.00 |
|
J Thorac Oncol |
2.206 |
6.00 |
|
Mol Med Rep |
2.100 |
17.00 |
|
Pathol Res Pract |
2.059 |
12.00 |
|
Med Sci Monitor |
1.918 |
15.00 |
|
Exp Ther Med |
1.785 |
12.00 |
|
Medicine |
1.552 |
23.00 |
|
J Int Med Res |
1.287 |
6.00 |
|
Com Chem High T Sci |
1.195 |
9.00 |
|
J Comput Biol |
1.054 |
10.00 |
想知道高分文章idea？哈哈，多看文章多总结！下面我们列举出了最新的高分文章，影响因子均在10分以上。
|
文章标题（IF>10） |
|
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. |
|
Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p |
|
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning |
|
Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning |
|
ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate |
|
FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to |
|
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer |
|
A user guide for the online exploration and visualization of PCAWG data. |
|
Sex differences in oncogenic mutational processes. |
|
Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples |
|
TIMER2.0 for analysis of tumor-infiltrating immune cells. |
|
CVCDAP: an integrated platform for molecular and clinical analysis of cancer virtual cohorts |
|
Weakly Supervised Deep Learning for Whole Slide Lung Cancer Image Analysis. |
|
Reference-free deconvolution, visualization and interpretation of complex DNA methylation data using DecompPipeline, MeDeCom and FactorViz |
|
Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors |
|
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden |
|
TET1 promotes malignant progression of cholangiocarcinoma with IDH1 wild-type. |
|
Whole Exome Profiling of NSCLC Among African Americans. |
|
Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. |
|
TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations |
|
Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC |
|
Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8 + T Cells and Elevated β-Catenin Activation Compared with Squamous Cell Carcinoma |
|
TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial |
|
A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma |
|
Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy |
|
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression |
|
Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma |
|
Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance) |
什么？10+文章太难搞！那我们再来看看5-10分都有哪些文章
影响因子在5-10分的杂志里Cancers 发布的纯生信文章最多，但是竟还是几乎没有中国单位发表的。。。好吧，下面我们只列举既对生信文章友好，又对中国单位友好的期刊Genomics、J Cell Physiol、Cancer Immunol Immunother的生信文章列表。（想投5-10分的纯生信文章，这三个期刊是首选哦！）
|
文章标题（10>IF>5） |
|
Prognostic significance of ARL9 and its methylation in low-grade glioma. |
|
Estimating gene expression from DNA methylation and copy number variation: A deep |
|
Minimum error calibration and normalization for genomic copy number analysis. |
|
Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer |
|
Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma |
|
Identification and validation of a six-lncRNA prognostic signature with its ceRNA networks and candidate drugs in lower-grade gliomas |
|
Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment |
|
Analysis of relapse-associated alternative mRNA splicing and construction of a prognostic signature predicting relapse in I-III colon cancer |
|
Identification of angiotensin-converting enzyme 2 (ACE2) protein as the potential biomarker in SARS-CoV-2 infection-related lung cancer using computational analysis |
|
Clinical and genomic characterization of neutral tumor evolution in Head and Neck Squamous Cell Carcinoma |
|
CancerEnD: A database of cancer associated enhancers. |
|
Construction and validation of a TP53-associated immune prognostic model for gastric cancer |
|
A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors |
|
Identifying potential DNA methylation markers in early-stage colorectal Cancer. |
|
A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis |
|
The chromosome 19 microRNA cluster, regulated by promoter hypomethylation, is associated with tumour burden and poor prognosis in patients with hepatocellular carcinoma |
|
DNA methylation data-based prognosis-subtype distinctions in patients with esophageal carcinoma by bioinformatic studies |
|
A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer |
|
The prognostic value and potential subtypes of immune activity scores in three major urological cancers |
|
Identification of novel genes in testicular cancer microenvironment based on ESTIMATE algorithm-derived immune scores |
|
Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma |
|
Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma |
|
PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model |
|
Bioinformatic identification of key pathways, hub genes, and microbiota for therapeutic intervention in Helicobacter pylori infection |
|
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC |
|
Tumor immune microenvironment in cancer patients with leukocytosis. |
|
Tumor-infiltrating CD39 + CD8 + T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients |
|
Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC) |
|
ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer |
|
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study |
|
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models |
|
Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8 + T cells in gastric cancer |
|
Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets |
|
Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis |
点击数：0